The concept of the leukaemic stem cell (LSC) is well established in AML and the frequency of the CD34+CD38− stem cell compartment with aberrant marker expression has proven predictive of adverse outcome in several studies (Vergez et al, 2011; Terwijn et al, 2014). This evidence concerns the gene CD38 and acute myeloid leukemia.